ISSN 2063-5346
For urgent queries please contact : +918130348310

The Effectiveness of XtraBos™ in Osteoarthritis and its Comorbidities in an In-Home User Trial (iHUT)

Main Article Content

Robert Ayton, Jamie Grover, Nalin Shukla, Snigdha Suman Dalua, Poorva Tiwari, R. Valavan
» doi: 10.48047/ecb/2023.12.9.250


Osteoarthritis (OA) is a prevalent musculoskeletal condition associated with significant pain, functional limitations, and reduced quality of life. Comorbidities like hypertension (HT), neuropathic pain (NP) and insomnia frequently coexist with OA. Addressing these conditions alongside OA treatment can improve pain management and enhance overall well-being. By targeting NP and sleep disorders, healthcare professionals can enhance treatment outcomes and patient compliance in OA management. Boswellia serrata extracts, including 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), have been found to be beneficial in OA recently. AKBA has also been found beneficial in many comorbidities of OA, especially HT. Boswellia serrata is known for its potent anti-inflammatory properties. The resin extracted from this plant contains bioactive compounds, such as 3-O-acetyl-11-keto-β-boswellic acid (AKBA), which have been extensively studied for their ability to combat inflammation. This study aims to investigate the efficacy and safety of XtraBos™, a herbal nutraceutical product, which is a standardised Boswellia serrata extract, in the management of OA and its comorbidities. It assessed the changes in the symptoms of OA, neuropathic pain & insomnia.

Article Details